Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03831503
Recruitment Status : Active, not recruiting
First Posted : February 5, 2019
Last Update Posted : June 13, 2022
Sponsor:
Collaborator:
Inovio Pharmaceuticals
Information provided by (Responsible Party):
University of Pennsylvania

Brief Summary:
Phase 1, open label, single center, dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of dMAb-ZK190 following delivery of INO-A002 with Hylenex® recombinant delivered IM followed by EP in healthy adult Dengue naïve volunteers ages 18-60 years.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Biological: INO-A002 Device: CELLECTRA® 2000 Device: Dengue Fever Antibodies (IgG) Phase 1

Detailed Description:

This is a Phase 1, open label, single center, dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of dMAb-ZK190 following delivery of INO-A002 with Hylenex® recombinant delivered IM followed by EP in healthy adult Dengue naïve volunteers ages 18-60 years.

The study will apply a 3+3 design such that 3 additional subjects will be enrolled into the cohort if one DLT (Section 7.3.1) is observed in one out of the first 3 subjects dosed during the 28-day period of safety and PK assessment. If no additional DLT is observed in 3 additional subjects (i.e., 1 DLT in 6 total subjects), dosing will proceed to the subsequent cohort. However, if any additional DLT occurs (i.e., >1 DLT in 6 total subjects), then that dose will be deemed not tolerated and the prior dose will be considered the maximum tolerated dose (MTD).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: This study will adhere to a dose escalation scheme. There are five cohorts for Study ZIKA-dMAb 01. Participants (n=6 per cohort) will be administered INO-A002 at four dose levels: 0.5, 1, 2, and 4 mg DNA/dose.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 1 Study of INO-A002 in Healthy Dengue Virus-naive Adults
Actual Study Start Date : February 7, 2019
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : November 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dengue

Arm Intervention/treatment
Experimental: Cohort A - 0.5mg
Participants (n=6 per cohort) will be administered 1 injection (Day 0) of INO-A002 at 0.5 mg DNA/dose. Inoculation will be administered as 0.5 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
Biological: INO-A002
Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).

Device: CELLECTRA® 2000
Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.

Device: Dengue Fever Antibodies (IgG)
To determine if the subject is Dengue seronegative at baseline

Experimental: Cohort B - 1mg
Participants (n=6 per cohort) will be administered 1 injection (Day 0) of INO-A002 at 1 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
Biological: INO-A002
Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).

Device: CELLECTRA® 2000
Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.

Device: Dengue Fever Antibodies (IgG)
To determine if the subject is Dengue seronegative at baseline

Experimental: Cohort C - 2mg
Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 2 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
Biological: INO-A002
Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).

Device: CELLECTRA® 2000
Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.

Device: Dengue Fever Antibodies (IgG)
To determine if the subject is Dengue seronegative at baseline

Experimental: Cohort D - 4mg
Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 4 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
Biological: INO-A002
Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).

Device: CELLECTRA® 2000
Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.

Device: Dengue Fever Antibodies (IgG)
To determine if the subject is Dengue seronegative at baseline

Experimental: Cohort E - 4mg Side Port
Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 4 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device with Side Port needle.
Biological: INO-A002
Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).

Device: CELLECTRA® 2000
Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.

Device: Dengue Fever Antibodies (IgG)
To determine if the subject is Dengue seronegative at baseline




Primary Outcome Measures :
  1. Evaluate the safety of escalating doses of INO-A002 with Hylenex® administered IM followed by electroporation with the CELLECTRA® 2000 device in healthy adult volunteers. [ Time Frame: 52 weeks ]
    Safety will be assessed by monitoring the frequency and severity of adverse events utilizing the "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials" with labs assessed as per site normal values.

  2. Evaluate the tolerability of escalating doses of INO-A002 with Hylenex® administered IM followed by electroporation with the CELLECTRA® 2000 device in healthy adult volunteers. [ Time Frame: 10 minutes ]
    Pain will be assessed by administration (i.e., injection) site reactions (frequency and severity) and visual analogue scale (VAS) scores.

  3. Determine the maximum serum concentration (Cmax) of the monoclonal antibody dMAb-ZK190 in the serum upon administration of INO-A002 with Hylenex® delivered IM followed by electroporation. [ Time Frame: 52 weeks ]
    The maximum serum concentration (Cmax) assessment will be performed by the analysis of dMAb-ZK190 levels at baseline; days 1, 3, 7 and at weeks 2, 3, 4, 5, 6, 8, 12, 16, 24 and 52. Serum concentration in micrograms/mL will be used as the measurement scale.

  4. Determine the minimum serum concentration (Cmin) of the monoclonal antibody dMAb-ZK190 in the serum upon administration of INO-A002 with Hylenex® delivered IM followed by electroporation. [ Time Frame: 52 weeks ]
    The minimum serum concentration (Cmin) assessment will be performed by the analysis of dMAb-ZK190 levels at baseline; days 1, 3, 7 and at weeks 2, 3, 4, 5, 6, 8, 12, 16, 24 and 52. Serum concentration in micrograms/mL will be used as the measurement scale.

  5. Determine the Area Under the Curve (AUC0-t) of the monoclonal antibody dMAb-ZK190 in the serum upon administration of INO-A002 with Hylenex® delivered IM followed by electroporation [ Time Frame: 52 weeks ]
    The Area Under the Curve (AUC0-t) will be performed by the analysis of dMAb-ZK190 levels at baseline; days 1, 3, 7 and at weeks 2, 3, 4, 5, 6, 8, 12, 16, 24 and 52. The Area Under the Curve (AUC0-t) against time will be calculated using the trapezoidal method.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria
  1. Age 18-60 years;
  2. Able to provide consent to participate and having signed an Informed Consent Form (ICF);
  3. Able and willing to comply with all study procedures;
  4. Body mass index (BMI) between 20 and 30, inclusive
  5. Screening laboratory must be within normal limits or have only Grade 0-1 findings;
  6. Normal screening ECG or screening ECG with no clinically significant findings;
  7. Women of child-bearing potential agree to use medically effective contraception (oral contraception, barrier methods, spermicide with barrier methods, etc.) or have a partner who is sterile from enrollment to 6 months following the last injection, or have a partner who is medically unable to induce pregnancy.
  8. Sexually active men who are considered sexually fertile must agree to use either a barrier method of contraception during the study, and agree to continue the use for at least 6 months following the last injection, or have a partner who is permanently sterile or is medically unable to become pregnant;
  9. No history of clinically significant immunosuppressive or autoimmune disease. Individuals with HIV infection who have been virologically suppressed for more than 1 year and with current CD4 cell count entry greater than 500 cells/ul will be allowed into the study.
  10. No history of dengue virus vaccination or illness; no history of yellow fever vaccination.
  11. Dengue seronegative at baseline by screening laboratory evaluation
  12. Not currently or within the previous 4 weeks taking immunosuppressive agents (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or prednisone at a dose less than 10 mg/day or steroid dose-equivalent).

Exclusion Criteria:

  1. Administration of an investigational compound either currently or within 30 days of first dose;
  2. Previous receipt of an investigational product for the treatment or prevention of Zika virus except if participant is verified to have received placebo;
  3. Administration of any vaccine within 4 weeks of first dose;
  4. Administration of any monoclonal or polyclonal antibody product within 4 weeks of the first dose
  5. Administration of any blood product within 3 months of first dose;
  6. Pregnancy or breast feeding or plans to become pregnant during the course of the study;
  7. Positive serologic result for dengue virus (any serotype) or history of receipt of either dengue virus or yellow fever virus vaccination at any time in the past;
  8. Positive serologic test for hepatitis B surface antigen (HBsAg); or any potentially communicable infectious disease as determined by the Principal Investigator or Medical Monitor;
  9. Positive serologic test for hepatitis C (exception: successful treatment with confirmation of sustained virologic response);
  10. Baseline evidence of kidney disease as measured by creatinine greater than 1.5 (CKD Stage II or greater);
  11. Baseline screening lab(s) with Grade 2 or higher abnormality, except for Grade 2 creatinine;
  12. Chronic liver disease or cirrhosis;
  13. Immunosuppressive illness including hematologic malignancy, history of solid organ or bone marrow transplantation;
  14. Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or prednisone at a dose greater than 10 mg/day or steroid dose-equivalent);
  15. Current or anticipated treatment with TNF-α inhibitors such as infliximab, adalimumab, etanercept;
  16. Prior major surgery or any radiation therapy within 4 weeks of group assignment;
  17. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;
  18. Presence of a cardiac pacemaker or automatic implantable cardioverter defibrillator (AICD)
  19. Fewer than two acceptable sites available for IM injection and EP considering the deltoid and anterolateral quadriceps muscles. The following are unacceptable sites:

    • Tattoos, keloids or hypertrophic scars located within 2 cm of intended administration site;
    • Implantable-Cardioverter-defibrillator (ICD) or pacemaker (to prevent a life-threatening arrhythmia) that is located ipsilateral to the deltoid injection site (unless deemed acceptable by a cardiologist);
    • Any metal implants or implantable medical device within the electroporation site.
  20. Prisoner or participants who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness;
  21. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; or
  22. Not willing to allow storage and future use of samples for Zika virus related research
  23. Any illness or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint.
  24. Participants who plan to travel within 6 months of INO-A002 administration to a geographic location where DENV or ZIKV are currently active.
  25. Participants with known bleeding diatheses or that are using blood thinners for 30 days before study enrollment including warfarin, heparin, Clopidogrel, Apixaban (Eliquis), Dabigatran (Pradaxa), Edoxaban (Savaysa), Rivaroxaban (Xarelto). The use of low dose aspirin (81 mg daily) will be acceptable.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03831503


Locations
Layout table for location information
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
Inovio Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Pablo Tebas, MD University of Pennsylvania
Layout table for additonal information
Responsible Party: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT03831503    
Other Study ID Numbers: 832135
First Posted: February 5, 2019    Key Record Dates
Last Update Posted: June 13, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Dengue
Arbovirus Infections
Vector Borne Diseases
Infections
Virus Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections
Hemorrhagic Fevers, Viral
Antibodies
Immunologic Factors
Physiological Effects of Drugs